Patents Assigned to Leukos Biotech, S.L.
  • COMBINATION THERAPY FOR TREATING CANCER
    Publication number: 20230122940
    Abstract: The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR 1)modulator, e.g. a HTR1 antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy.
    Type: Application
    Filed: August 10, 2022
    Publication date: April 20, 2023
    Applicant: LEUKOS BIOTECH, S.L.
    Inventors: Ruth MUÑOZ RISUEÑO, Mari Carmen LARA CASTILLO, Amaia ETXABE ALBERDI
  • Combination therapy for treating cancer
    Patent number: 11446321
    Abstract: The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR1) modulator, e.g. a HTR1 antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy.
    Type: Grant
    Filed: January 15, 2018
    Date of Patent: September 20, 2022
    Assignee: Leukos Biotech, S.L.
    Inventors: Ruth Muñoz Risueño, Mari Carmen Lara Castillo, Amaia Etxabe Alberdi
  • Apomorphine-palmitic acid cocrystal solid particle crystalline form
    Patent number: 11382867
    Abstract: A pharmaceutical composition comprising apomorphine (APO) in a solid crystalline form, wherein the solid crystalline form is an APO·palmitic acid cocrystal solid particle crystalline form.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: July 12, 2022
    Assignee: LEUKOS BIOTECH, S. L.
    Inventors: Enrique Llaudet Carles, Nicolas Tesson, Montserrat Trilla Castaño
  • Combination Therapy For Treating Cancer
    Publication number: 20190365792
    Abstract: The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR1) modulator, e.g. a HTR1 antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy.
    Type: Application
    Filed: January 15, 2018
    Publication date: December 5, 2019
    Applicant: Leukos Biotech, S.L.
    Inventors: Ruth MUÑOZ RISUEÑO, Mari Carmen LARA CASTILLO, Amaia ETXABE ALBERDI